ara-290 dosage: Frequently asked questions

Discard it. Even 8–12 hours at room temperature (20–25°C) degrades reconstituted peptide by 20–40%, and there's no reliable home test to confirm remaining potency. The financial loss hurts, but injecting degraded peptide wastes injection frequency, skews your assessment of therapeutic response, and introduces variables that make it impossible to determine whether lack of benefit is due to the peptide or the protocol. Temperature-stable storage isn't optional. It's the single most common point of failure in self-administered peptide protocols.

Start at 4mg three times weekly. The Diabetes Care 2017 trial showed that 4mg produced meaningful pain reduction (1.8-point NRS decrease) and IENFD stabilisation with minimal injection site reactions (12% incidence). The 8mg cohort had only marginally better pain scores (2.4-point decrease) but 38% injection site reaction rate. Diabetic SFN responds to lower-dose IRR activation because the primary pathology is metabolic (hyperglycemia-driven oxidative stress and advanced glycation end products), not acute neurotoxic injury. If 4mg shows no response after 8 weeks, escalation to 6mg is reasonable, but most diabetic neuropathy patients who respond do so at the 4mg dose.

Move to a higher-frequency protocol (daily at 2–3mg) before increasing per-dose amount. Some individuals show delayed IRR upregulation, and more frequent receptor engagement can overcome low baseline expression. If no subjective or objective improvement appears by week 8–10, the issue likely isn't dose. It's either poor peptide quality, incorrect storage handling, or you're not in a disease state where IRR activation provides measurable benefit. ARA-290 works by dampening active inflammatory processes; in the absence of neuroinflammation, there's no signal to amplify.

Your concentration drops from 2.5 mg/mL to 1.67 mg/mL. To deliver the same 4 mg dose, withdraw 2.4 mL instead of 1.6 mL. The peptide mass remains unchanged. Only the volume increases. This is not a dosing error as long as you recalculate volume based on the new concentration. The downside: larger injection volumes are less comfortable for repeated subcutaneous dosing, and you'll exhaust the vial faster. If this happens, label the vial with the correct concentration immediately to prevent future calculation mistakes.

Cloudiness indicates protein aggregation or contamination. Do not use it. ARA-290 should appear clear and colorless after reconstitution. Aggregation can result from temperature excursions (left out of refrigerator for more than 2 hours), repeated freeze-thaw cycles, or contamination from non-sterile needle punctures. Discard the vial and reconstitute a fresh one. This is why multi-dose vials should be accessed using sterile technique every time. Wipe the rubber stopper with alcohol before each needle insertion.

Scale the dose proportionally: 2 mg/kg for a 320-gram rat equals 0.64 mg per injection. At 2.5 mg/mL concentration, withdraw 0.256 mL (approximately 26 units). Most insulin syringes allow single-unit precision, so round to 26 units. The 0.004 mL difference (0.01 mg peptide) falls within acceptable experimental variance. For studies requiring tighter dose control, weigh animals weekly and adjust dose calculations. Body weight can shift 5–10% across multi-week protocols, particularly in metabolic or injury models.

Each mouse requires 0.05 mg ARA-290. For 15 mice, total dose is 0.75 mg. At 2.5 mg/mL, you need 0.3 mL total. Prepare a working stock: withdraw 0.3 mL from your reconstituted vial, dilute it in 1.5 mL sterile saline for a final concentration of 0.5 mg/mL, and administer 0.1 mL (10 units) per mouse. This increases injection volume to 0.1 mL per dose, improving measurement accuracy and reducing syringe dead-space loss. Use the working stock within 24 hours and keep it refrigerated between injections.

Verify by reverse-calculating: if your target dose is 4 mg and you're withdrawing 1.6 mL, divide dose by volume: 4 mg ÷ 1.6 mL = 2.5 mg/mL. This should match your intended reconstitution (5 mg powder ÷ 2 mL water = 2.5 mg/mL). If the numbers don't align, recheck your reconstitution volume and syringe measurement. A second common error: forgetting that the powder itself has negligible volume. Adding 2 mL water to a 5 mg vial yields 2 mL final volume, not 2.1 mL.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.